Clinical trial
A Phase III Study of Abatacept in Japanese Subjects With Rheumatoid Arthritis
NCT00484289 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT00484289 |
|---|---|
| Title | A Phase III Study of Abatacept in Japanese Subjects With Rheumatoid Arthritis |
| Official title | A Phase III, Multi-center, Open-label, Uncontrolled, Long-term Study to Evaluate the Safety of Abatacept (BMS-188667) in Japanese Subjects With Rheumatoid Arthritis Having Completed Clinical Studies IM101-071, IM101-034, and Also Special DMARD Failures |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Rheumatoid Arthritis |
| Intervention type | Drug |
| Interventions | Abatacept |
| Enrollment | 217 |
| Start date | Dec 1, 2006 |
| Primary completion | Dec 1, 2010 |
| Completion | Dec 1, 2010 |
| First posted | Jun 8, 2007 |
| Last update posted | Jun 24, 2013 |
| Countries | Japan |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: